Lucid Capital initiated coverage of I-Mab (IMAB) with a Buy rating and $5 price target I-Mab is a clinical-stage biotechnology company focused on precision therapeutics for the treatment of cancer, the analyst tells investors in a research note. The firm believes the company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig, could be a significant value driver for shares, approaching the top-line Phase 1b combination dose escalation and dose expansion data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB: